drugset / Trial / NCT05235906
A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
The efficacy and safety of the use of Surufatinib in combination with Sintilimab.
Timeline
- Start
- 2022-08-16
- Primary completion
- 2024-03-31
- Completion
- 2025-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Surufatinib | Small molecule | 250 mg | — |